Eli Lilly entered 2026 from a position of exceptional growth. Revenue increased 45% to $65.2 billion in 2025, while net income nearly doubled to $20.6 billion. The company’s growth is increasingly driven by cardiometabolic medicines, particularly Mounjaro and Zepbound, while Lilly continues investing heavily in R&D, manufacturing capacity, and new therapeutic platforms.
The following Eli Lilly SWOT Analysis 2026 is based strictly on the company’s 2025 Annual Report.
Eli Lilly Business Model 2026: How Does Eli Lilly Make Money?
Strengths
1. Dominant Growth From Mounjaro and Zepbound
Mounjaro generated $22.97 billion and Zepbound $13.54 billion in 2025. Together, they accounted for 56% of Lilly’s total revenue and established cardiometabolic health as the company’s primary growth engine.
2. Exceptional Revenue and Profit Growth
Lilly’s revenue rose from $45.0 billion in 2024 to $65.2 billion in 2025, while net income increased from $10.6 billion to $20.6 billion. Gross margin also improved to 83%, demonstrating strong operating leverage from favorable product mix and higher volumes.
3. Strong R&D Capability
Lilly invested $13.34 billion in R&D in 2025, including $4.88 billion in early-stage and $8.46 billion in late-stage development. Management allocates resources based on technical success probability, unmet medical need, and commercial viability, supporting both current and future growth.
4. Broad Therapeutic Portfolio
Beyond cardiometabolic health, Lilly has established franchises in oncology, immunology, and neuroscience. Products such as Verzenio, Taltz, Ebglyss, Omvoh, Emgality, and Kisunla provide additional revenue sources and reduce complete dependence on a single therapeutic market.
5. Strong Intellectual Property Protection
Patent and regulatory exclusivity support the economics of Lilly’s innovation model. Mounjaro/Zepbound compound patent protection is expected to extend to 2036 in the U.S., 2037 in major European markets, and 2040 in Japan.
Eli Lilly Business Strategy 2026
Weaknesses
1. Heavy Dependence on a Small Number of Products
Six medicines accounted for 82% of total 2025 revenue, while Mounjaro and Zepbound alone represented 56%. This creates substantial concentration risk if demand, safety, pricing, reimbursement, competition, or regulation adversely affects key products.
2. High Manufacturing Capital Requirements
Lilly spent $7.8 billion on capital expenditures in 2025, up from $5.1 billion in 2024, and expects meaningfully higher spending as it expands manufacturing capacity. Rapid growth therefore requires significant ongoing capital commitments.
3. Significant Dependence on U.S. Revenue
The U.S. generated $43.5 billion, or approximately two-thirds of Lilly’s 2025 revenue. This leaves the company particularly exposed to U.S. healthcare policy, reimbursement rules, government pricing initiatives, PBMs, and payer negotiations.
4. Concentrated Distribution Network
Lilly depends heavily on a small group of large wholesalers. Each of its three largest wholesalers accounted for between 16% and 24% of consolidated revenue, creating operational and receivables concentration within the distribution system.
5. Growth Requires Continuous Innovation
Pharmaceutical products eventually face patent expiry, generic or biosimilar competition, and changing treatment standards. Lilly therefore must continuously invest large amounts in R&D and acquisitions to replace mature products and preserve long-term growth.
Eli Lilly PESTEL Analysis 2026
Opportunities
1. Continued Global Expansion of Mounjaro
Mounjaro’s revenue outside the U.S. increased from $2.6 billion in 2024 to $9.3 billion in 2025, driven mainly by volume growth. Further international penetration could significantly expand Lilly’s cardiometabolic franchise.
2. Orforglipron Could Broaden the Obesity Franchise
Orforglipron has been submitted for regulatory review in the U.S., EU, and Japan for obesity or overweight and received an FDA Commissioner’s National Priority Voucher. If approved, it could broaden Lilly’s cardiometabolic offering beyond current products.
3. Expanded Patient Access Through LillyDirect
LillyDirect represented a growing portion of Lilly’s business in 2025. By combining digital access, third-party pharmacy fulfillment, and patient-support tools, Lilly can expand cash-pay and alternative-access channels where traditional insurance coverage remains limited.
4. External Innovation Through Acquisitions and Licensing
Lilly actively uses acquisitions, collaborations, investments, and licensing to strengthen its pipeline. The acquisition of Verve Therapeutics adds genetic medicines for cardiovascular disease and demonstrates Lilly’s willingness to enter new therapeutic modalities.
5. Expansion in Oncology, Immunology and Neuroscience
Lilly generated substantial revenue beyond cardiometabolic health, including approximately $9.4 billion from oncology and more than $5 billion from immunology. Continued pipeline development in these areas could create additional large franchises and diversify long-term earnings.
Threats
1. Government Drug Pricing Pressure
Jardiance is subject to government-set Medicare pricing beginning in 2026, while Trulicity and Verzenio were selected for pricing beginning in 2028. Lilly expects additional products could be selected, potentially accelerating revenue erosion.
2. Increasing Competition in Obesity and Other Therapeutic Areas
Lilly operates in highly competitive pharmaceutical markets where success depends on efficacy, safety, patient preference, access, pricing, reimbursement, and speed to market. Competing products or modalities can reduce sales and force price concessions.
3. Generic and Biosimilar Competition
When patent or regulatory exclusivity ends, generic and biosimilar manufacturers can enter with much lower development costs and prices. Lilly states that branded medicines can lose a significant portion of revenue very quickly after market exclusivity expires.
4. Counterfeit and Compounded Incretin Products
Lilly continues to face counterfeit, misbranded, adulterated, and mass-compounded incretin medicines. These products may create patient-safety concerns, consumer confusion, lost sales, pricing pressure, and reputational risk.
5. Manufacturing and Regulatory Disruptions
Failures related to manufacturing quality, cGMP compliance, safety signals, impurities, or regulatory inspections can result in recalls, production interruptions, shortages, import restrictions, fines, and delays in product approvals, potentially materially affecting revenue and reputation.
Source: Eli Lilly Annual Report
